Chimerix (CMRX) News Today $0.86 -0.04 (-4.44%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Chimerix’s Phase 2 Reassessment Boosts Buy Rating Amid Promising Data and Strong FinancialsNovember 12, 2024 | markets.businessinsider.comChimerix announces updates Phase 2 data at 2024 SNO meetingNovember 11, 2024 | markets.businessinsider.comChimerix’s Dordaviprone Shows Promising Efficacy in H3 K27M-mutant Diffuse Glioma with $11 Price TargetNovember 11, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a report on Monday.November 11, 2024 | marketbeat.comChimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNovember 11, 2024 | finanznachrichten.deChimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO MeetingNovember 11, 2024 | markets.businessinsider.comWedbush Reaffirms Outperform Rating for Chimerix (NASDAQ:CMRX)November 9, 2024 | americanbankingnews.comChimerix’s Strategic Regulatory Progress and Market Potential Bolster Buy RatingNovember 8, 2024 | markets.businessinsider.comChimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...November 8, 2024 | finance.yahoo.comChimerix, Inc. (CMRX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comChimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of EarningsNovember 6, 2024 | finance.yahoo.comChimerix (CMRX) Scheduled to Post Quarterly Earnings on ThursdayChimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Shares Cross Above Two Hundred Day Moving Average - Here's WhyChimerix (NASDAQ:CMRX) Stock Price Crosses Above 200 Day Moving Average - What's Next?November 2, 2024 | marketbeat.comChimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024November 1, 2024 | globenewswire.comChimerix (NASDAQ:CMRX) Share Price Passes Below Two Hundred Day Moving Average - What's Next?Chimerix (NASDAQ:CMRX) Stock Passes Below Two Hundred Day Moving Average - What's Next?October 25, 2024 | marketbeat.comChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)October 18, 2024 | globenewswire.comChimerix, Inc. (NASDAQ:CMRX) Short Interest UpdateChimerix, Inc. (NASDAQ:CMRX - Get Free Report) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,800,000 shares, a drop of 6.7% from the September 15th total of 1,930,000 shares. Based on an average daily volume of 456,700 shares, the short-interest ratio is presently 3.9 days. Currently, 2.3% of the shares of the stock are sold short.October 17, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comChimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average - What's Next?Chimerix (NASDAQ:CMRX) Stock Price Passes Above 200-Day Moving Average - Time to Sell?October 5, 2024 | marketbeat.comHere's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn SituationSeptember 23, 2024 | finance.yahoo.comChimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.95Chimerix (NASDAQ:CMRX) Shares Cross Below 200-Day Moving Average of $0.95September 20, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Share Price Passes Below 200 Day Moving Average of $0.96Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.96September 12, 2024 | marketbeat.comChimerix to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Shares Cross Below 200 Day Moving Average of $0.97Chimerix (NASDAQ:CMRX) Share Price Crosses Below Two Hundred Day Moving Average of $0.97September 3, 2024 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short InterestChimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,690,000 shares, a drop of 10.6% from the July 31st total of 1,890,000 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily volume of 485,300 shares, the days-to-cover ratio is currently 3.5 days.September 1, 2024 | marketbeat.comChimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 30, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Chimerix (CMRX) and Ocuphire Pharma (OCUP)August 22, 2024 | markets.businessinsider.comChimerix Inc (CXF.DU)August 21, 2024 | uk.finance.yahoo.comShort Interest in Chimerix, Inc. (NASDAQ:CMRX) Expands By 18.1%Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a significant increase in short interest in July. As of July 31st, there was short interest totalling 1,890,000 shares, an increase of 18.1% from the July 15th total of 1,600,000 shares. Based on an average daily volume of 213,100 shares, the days-to-cover ratio is presently 8.9 days. Currently, 2.4% of the company's stock are short sold.August 16, 2024 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Expected to Post Q1 2025 Earnings of ($0.24) Per ShareChimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush dropped their Q1 2025 earnings estimates for Chimerix in a note issued to investors on Tuesday, August 13th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.24) per sharAugust 16, 2024 | marketbeat.comEquities Analysts Offer Predictions for Chimerix, Inc.'s FY2028 Earnings (NASDAQ:CMRX)Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities researchers at Capital One Financial reduced their FY2028 EPS estimates for shares of Chimerix in a research note issued on Tuesday, August 13th. Capital One Financial analyst N. Quibria now forecasts that the biopharmaceutical company will eaAugust 15, 2024 | marketbeat.comQ2 2024 Chimerix Inc Earnings CallAugust 14, 2024 | finance.yahoo.comChimerix, Inc. (CXF.F)August 14, 2024 | nz.finance.yahoo.comWHO declares mpox in Africa is a global health emergencyAugust 14, 2024 | msn.comChimerix, Inc. (NASDAQ:CMRX) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comHC Wainwright Reaffirms Buy Rating for Chimerix (NASDAQ:CMRX)HC Wainwright restated a "buy" rating and set a $11.00 target price on shares of Chimerix in a report on Wednesday.August 14, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Announces Quarterly Earnings ResultsChimerix (NASDAQ:CMRX - Get Free Report) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. The business had revenue of $0.13 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter last year, the business posted ($0.21) EPS.August 14, 2024 | marketbeat.comChimerix's (CMRX) Outperform Rating Reaffirmed at WedbushWedbush restated an "outperform" rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday.August 13, 2024 | marketbeat.comSwiss Funding Bodies ‘Talk Money’ and Co-Financing Opportunities at Locarno: ‘We Create a Space Where Stories Take Shape’August 13, 2024 | msn.comChimerix earnings preview: what Wall Street is expectingAugust 13, 2024 | markets.businessinsider.comChimerix Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 13, 2024 | finance.yahoo.comChimerix, Inc. (CMRX) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comChimerix Q2 2024 Earnings PreviewAugust 12, 2024 | msn.comChimerix (CMRX) Scheduled to Post Earnings on TuesdayChimerix (NASDAQ:CMRX) will be releasing earnings before the market opens on Tuesday, August 13, Zacks reports.August 7, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Stock Crosses Below 200 Day Moving Average of $0.99Chimerix (NASDAQ:CMRX) Stock Price Crosses Below 200-Day Moving Average of $0.99July 9, 2024 | marketbeat.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 5, 2024 | globenewswire.comChimerix (NASDAQ:CMRX) Shares Pass Below 200-Day Moving Average of $0.99Chimerix (NASDAQ:CMRX) Stock Crosses Below 200 Day Moving Average of $0.99June 29, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Stock Price Passes Below Two Hundred Day Moving Average of $0.99Chimerix (NASDAQ:CMRX) Share Price Crosses Below Two Hundred Day Moving Average of $0.99June 18, 2024 | marketbeat.comVestal Point Capital LP Invests $1.35 Million in Chimerix, Inc. (NASDAQ:CMRX)Vestal Point Capital LP bought a new stake in Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,400,000 shares of the biopharmaceutical company's stock, valued at approximaJune 9, 2024 | marketbeat.comChimerix (NASDAQ:CMRX) Lifted to Hold at StockNews.comStockNews.com raised Chimerix from a "sell" rating to a "hold" rating in a research report on Saturday.June 8, 2024 | marketbeat.com Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military. Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t CMRX Media Mentions By Week CMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMRX News Sentiment▼0.590.56▲Average Medical News Sentiment CMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMRX Articles This Week▼91▲CMRX Articles Average Week Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Fortress Biotech News Today Nature's Sunshine Products News Today Sage Therapeutics News Today Voyager Therapeutics News Today Alpha Teknova News Today YS Biopharma News Today Kamada News Today Jasper Therapeutics News Today iTeos Therapeutics News Today Aurora Cannabis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMRX Stock Alerts